DrugPatentWatch Database Preview
Details for Patent: 6,455,518
Which drugs does patent 6,455,518 protect, and when does it expire?
Protection for ZORTRESS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-two patent family members in fifteen countries.
Summary for Patent: 6,455,518
Title: | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin |
Abstract: | A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin. |
Inventor(s): | Zenke; Gerhard (Rheinfelden, DE), Schuurman; Hendrik (Basel, CH), Haeberlin; Barbara (Riehen, CH), Meinzer; Armin (Buggingen, DE) |
Assignee: | Novartis AG (Basel, CH) |
Application Number: | 09/758,301 |
Patent Claim Types: see list of patent claims | Compound; Composition; Formulation; Use; Dosage form; Device; |
Drugs Protected by US Patent 6,455,518
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | ZORTRESS | everolimus | TABLET;ORAL | 021560-001 | Apr 20, 2010 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||||
Novartis | ZORTRESS | everolimus | TABLET;ORAL | 021560-002 | Apr 20, 2010 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||||
Novartis | ZORTRESS | everolimus | TABLET;ORAL | 021560-003 | Apr 20, 2010 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Foreign Priority and PCT Information for Patent: 6,455,518
Non-Orange Book US Patents Family Members for Patent 6,455,518
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
6,239,124 | Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin | ➤ Sign Up |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 6,455,518
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 222502 | ➤ Sign Up | |||
Austria | 340586 | ➤ Sign Up | |||
Australia | 4012497 | ➤ Sign Up | |||
Australia | 730781 | ➤ Sign Up | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |